FDA approves Amphastar’s generic teriparatide pen for high-risk osteoporosis, launching year-end.

The ACTION3 trial for DMX-200 in FSGS successfully enrolled 286 patients across 21 countries, showing early promise in reducing proteinuria.

MDCE launches first AI nutrition app in global testing, pending approval and public release.

IGC Pharma expects benefits from cannabis reclassification to Schedule III, advancing its Alzheimer’s drug trial and research.

Aytu BioPharma launches EXXUA, the first FDA-approved 5HT1a agonist for adult depression, with proven efficacy and no sexual dysfunction or weight gain in trials.

FDA now allows anonymized real-world data in medical device reviews to speed up approvals.

St. Jude's AI-driven platform Combocat accelerates discovery of effective drug combos for cancer and other diseases.

HKU launches dental innovation hub with up to HK$6M funding, targeting global startups in digital dentistry and AI.

Mount Sinai researchers created SMRTS, an mRNA system that targets cancer cells using cancer-specific microRNAs, boosting therapy accuracy and effectiveness in mice.

Genflow Biosciences finished dosing its canine gene therapy trial for GF-1002, a SIRT6-based treatment, with no adverse events and safety confirmed.